Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine
Different patterns of cutaneous leishmaniasis can be induced when a challenge of alike dose of Leishmania amazonensis amastigotes in various inbred strains was applied. Two strains of mice, the Balb/c and C57 BL/10J, showed exceptional suscepbility, and 10(elevado a sexta potência) amastigotes infec...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fundação Oswaldo Cruz (FIOCRUZ)
1992-01-01
|
| Series: | Memorias do Instituto Oswaldo Cruz |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000500010 |
| _version_ | 1797720744175599616 |
|---|---|
| author | Kátia da Silva Calabrese Sylvio Celso Gonçalves da Costa |
| author_facet | Kátia da Silva Calabrese Sylvio Celso Gonçalves da Costa |
| author_sort | Kátia da Silva Calabrese |
| collection | DOAJ |
| description | Different patterns of cutaneous leishmaniasis can be induced when a challenge of alike dose of Leishmania amazonensis amastigotes in various inbred strains was applied. Two strains of mice, the Balb/c and C57 BL/10J, showed exceptional suscepbility, and 10(elevado a sexta potência) amastigotes infective dose lead, to ulcerative progressive lesions with cutaneous metastasis and loss by necrosis of leg on wich the footpad primary lesion occured. Lesions were also progressive but in a lower degree when C3H/HeN and C57BL/6 were infected. Lesions progress slowly in DBA/2 mice presenting lesions wich reach a discreet peack after 12 weeks, do not heal but do not uncerate. DBA/2 mice is, therefore, a good model for immunomodualtion. In attempt to determine the influence of BCG in vaccination schedule using microsomal fraction, DBA/2 became an excellent model, since it is also a non-responder to BCG. Vaccination of DBA/2 mice, receiving the same 10(elevado a sexta potência) BCG viable dose and 10 *g or 50 *g of protein content of microsomal fraction, lead to a progressive disease with time course similar to those observed in susceptible non-vaccinated C57BL/10J mice after 6 months of observation. An enhancement of infection in BCG non-responder mice suggests that use of BCG as immunostimulant in humans could be critical for both vaccination and immunoprophylactic strategies. |
| first_indexed | 2024-03-12T09:23:55Z |
| format | Article |
| id | doaj.art-190f17599650419fb849a987a625fa8c |
| institution | Directory Open Access Journal |
| issn | 0074-0276 1678-8060 |
| language | English |
| last_indexed | 2024-03-12T09:23:55Z |
| publishDate | 1992-01-01 |
| publisher | Fundação Oswaldo Cruz (FIOCRUZ) |
| record_format | Article |
| series | Memorias do Instituto Oswaldo Cruz |
| spelling | doaj.art-190f17599650419fb849a987a625fa8c2023-09-02T14:21:06ZengFundação Oswaldo Cruz (FIOCRUZ)Memorias do Instituto Oswaldo Cruz0074-02761678-80601992-01-0187495610.1590/S0074-02761992000500010Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccineKátia da Silva CalabreseSylvio Celso Gonçalves da CostaDifferent patterns of cutaneous leishmaniasis can be induced when a challenge of alike dose of Leishmania amazonensis amastigotes in various inbred strains was applied. Two strains of mice, the Balb/c and C57 BL/10J, showed exceptional suscepbility, and 10(elevado a sexta potência) amastigotes infective dose lead, to ulcerative progressive lesions with cutaneous metastasis and loss by necrosis of leg on wich the footpad primary lesion occured. Lesions were also progressive but in a lower degree when C3H/HeN and C57BL/6 were infected. Lesions progress slowly in DBA/2 mice presenting lesions wich reach a discreet peack after 12 weeks, do not heal but do not uncerate. DBA/2 mice is, therefore, a good model for immunomodualtion. In attempt to determine the influence of BCG in vaccination schedule using microsomal fraction, DBA/2 became an excellent model, since it is also a non-responder to BCG. Vaccination of DBA/2 mice, receiving the same 10(elevado a sexta potência) BCG viable dose and 10 *g or 50 *g of protein content of microsomal fraction, lead to a progressive disease with time course similar to those observed in susceptible non-vaccinated C57BL/10J mice after 6 months of observation. An enhancement of infection in BCG non-responder mice suggests that use of BCG as immunostimulant in humans could be critical for both vaccination and immunoprophylactic strategies.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000500010Leishmania amazonensisinbred micevaccinationBCGmicrosomal fraction |
| spellingShingle | Kátia da Silva Calabrese Sylvio Celso Gonçalves da Costa Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine Memorias do Instituto Oswaldo Cruz Leishmania amazonensis inbred mice vaccination BCG microsomal fraction |
| title | Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine |
| title_full | Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine |
| title_fullStr | Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine |
| title_full_unstemmed | Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine |
| title_short | Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine |
| title_sort | enhancement of leishmania amazonensis infection in bcg non responder mice by bcg antigen specific vaccine |
| topic | Leishmania amazonensis inbred mice vaccination BCG microsomal fraction |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000500010 |
| work_keys_str_mv | AT katiadasilvacalabrese enhancementofleishmaniaamazonensisinfectioninbcgnonrespondermicebybcgantigenspecificvaccine AT sylviocelsogoncalvesdacosta enhancementofleishmaniaamazonensisinfectioninbcgnonrespondermicebybcgantigenspecificvaccine |